PTP Expression in Pediatric Lymphoma

lymphoma cases compared to lymphoid tissue. Knowledge about the expression of key regulatory proteins in pediatric B-cell lymphomas is necessary for revealing the complex molecular background of this disease.
Keywords Burkitt, immunohistochemistry, lymphoma, pediatric, protein tyrosine phosphatase Non-Hodgkin lymphoma (NHL) in children is primarily limited to four types of lymphoma: Burkitt lymphoma (BL), lymphoblastic lymphoma, diffuse large B-cell lymphoma (DLBCL), and anaplastic large cell lymphoma (ALCL), where BL is the most common subgroup, constituting about 40% of the cases [1] . BL is a highly aggressive lymphoma, with tumor cells that have a high proliferation rate and are phenotypically characterized by being CD10
+ , bcl6 + , and bcl2 − [2] . A high survival rate is obtained in children with pediatric BL today, due to effective therapeutic chemotherapy. However, precise diagnosis based on histologic, immunophenotypic, and genetic features is still critical when planning for the appropriate therapy [3] . The majority of BL and DLBCL have been suggested to be derived from lymph node germinal center (GC) regions, where rapidly proliferating Bcell blasts undergo somatic hypermutation of the immunoglobulin variable region gene during their differentiation to antibody-secreting plasma cells or memory B cells [4] . During the GC process, the B cells transform into malignant BL or DLBCL by either activation of proto-oncogenes or disruption of tumor suppressor genes.
Cells of the immune system, and thereby lymphoma, utilize a wide array of signaling networks, evoked by multiple cell surface receptors [5] . Reversible tyrosine phosphorylation of proteins is catalyzed by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) and functions as a key regulatory mechanism for a broad set of physiological processes in eukaryotes [6] . By dephosphorylating protein substrates, PTPs counteract the phosphorylating PTKs, and abnormalities in this process cause dysfunctional cell signaling and have been reported in many inherited or acquired human diseases. It is now known that 107 genes in the human genome encode members of four PTP families [7] . The largest group is the classical PTPs, comprising of 21 transmembrane and 17 nonreceptor PTPs [7, 8] .
Here, we provide novel data about the expression of nonreceptor phosphatases Src homology (SH) 2 domain-containing phosphatase (SHP)1, SHP2, phosphatase and tensin homolog (PTEN), and hematopoietic PTP (HePTP) in pediatric control lymphoid tissue and B-cell lymphoma tissue from children diagnosed with BL, DLBCL, or unspecified B-cell NHL. We show a lower staining intensity for cytoplasmic PTEN and HePTP in B-cell lymphoma tissue compared to control lymphoid tissue. Nuclear SHP2 was detected in a higher percentage of B cells in BL and LBCL cases compared to controls, whereas no significant differences were found in cytoplasmic SHP1 or SHP2 expression between normal and malignant B cells. Investigating the expression of key regulatory proteins in cell signaling pathways frequently mutated in cancer is of great importance for revealing the molecular background of pediatric lymphomas, and for designing better individual treatment of this disease in the future.
MATERIALS AND METHODS
Case Selection
Twenty-six formalin-fixed and paraffin-embedded lymphoid tissue samples of pediatric B-cell NHL lymphoma diagnosed at the University Hospital in Lund, Sweden, between 1982 and 2006, were reviewed and selected by two hematopathologists. Cases included in the study displayed classic morphologic and immunophenotypic features in accordance with WHO and Revised European-American classification criteria. The patients were children of the ages 1 to 17 years and the samples represented 19 BL, 2 DLBCL, 1 LBCL, and 4 cases diagnosed with "B-cell NHL" (B-NHL). Formalin-fixed and paraffin-embedded nonmalignant tonsils from 5 children were included as controls.
Immunohistochemical Methods
Representative areas in the paraffin blocks were chosen by a pathologist and a tissue microarray (TMA) was constructed as described previously [9] . In addition, one control TMA consisting of 5 cases of pediatric nonmalignant tonsils was constructed. Four-micrometer TMA sections were dried, deparaffinized, rehydrated, and microwave-treated for 10 min with target retrieval solution, pH 9.9. The sections were subsequently processed in an automatic immunohistochemistry staining machine (Techmate 500; Dako, Copenhagen, Denmark) with the following primary antibodies: mouse anti-human CD10 (Serotec, Oxford, UK), mouse anti-human Bcl6 (Chemicon/Millipore, Bedford, MA, USA), rabbit anti-human SHP1 and SHP2 (Santa Cruz Biotechnology, Santa Cruz, USA), rabbit anti-human PTEN and mouse anti-human PCNA (Cell Signaling, Danvers, MA, USA), mouse anti-human HePTP [10] , and mouse anti-human Bcl2 and mouse anti-human CD3 (Dako Cytomation, Copenhagen, Denmark). Incubation with secondary antibodies and visualization were performed with Dako real envision detection system peroxidase/DAB (Dako). Slides were counterstained with hematoxylin. All cases were blinded and analyses were performed independently by one pathologist and two researchers.
Due to poor quality in some material, all markers could not be validated in all samples. Staining intensity and percent stained tumor cells were PTP Expression in Pediatric Lymphoma 531 validated independently. The intensity was graded 0 if the case was negative for the marker, 1 if a weak staining was detected, 2 for a moderate staining, and 3 for a strong staining. For each marker, the staining intensity in the different tissue samples was scored in relation to the other cases on the same slide. Further, since normal controls in the case of HePTP displayed a stronger intensity compared to lymphoma cases, the normal controls were here given an additional grade 4 for statistical analyses. For scoring percent stained tumor cells, a 25% cutoff was used; 26-50% was considered an intermediate expression and 51-100% a high protein expression. In the nonmalignant TMA, the mature B cells were analyzed. There was a 90% agreement between the observers and, in cases of variance, the pathologist determined the outcome. For statistical analysis, Mann-Whitney tests were performed in SPSS for Windows 12.0.1 (2002, SPSS Inc.).
RESULTS
Patient Population
Tissue samples from 26 pediatric patients diagnosed with B-cell lymphomas, including 19 BL, 2 DLBCL, 1 LBCL (diagnosis indicates DLBCL or follicular lymphoma grade 3B), and 4 B-NHL, were analyzed in this study. The 2 DLBCL cases and the LBCL case were grouped together as LBCL. The median age was 8 years and the majority of cases were boys (Table 1 Table 1 ). The overall survival was 100% in the study population.
Highly Proliferating and GC-derived Tumors in the Majority of B-cell Lymphoma Cases
The samples were stained for the GC markers CD10 and Bcl6, for Bcl2 and CD3, and for the proliferation marker PCNA (Table 2) . With a 25% cutoff, 13 out of 16 analyzed BL were positive for CD10, demonstrating that the majority of BL tumors in this study are derived from GC B cells. The majority of BL cells were also positive for Bcl6. Two out of 3 LBCL and 3 out of 4 B-NHL cases were positive for CD10, also indicating that the tumor cells originate from mature, activated B cells. The anti-apoptotic marker Bcl2 was expressed in 5 out of 14 analyzed cases of BL, in 1 out of 3 LBCL and in 3 out of 4 B-NHL cases. PCNA staining analysis showed a very high proliferation index of the tumor cells in all cases. Infiltrating T cells were visualized by staining with a CD3 antibody and 4 out of the 13 analyzed BL cases displayed T cells above the cutoff level (25%). The LBCL cases were negative for CD3-positive T cells, whereas high numbers (>50%) of T cells were detected in 3 out of 4 B-NHL cases ( Table 2 ).
The Expression of PTPs SHP1, SHP2, PTEN, and HePTP in Control Lymphoid Tissue
Initially, lymphoid cells (tonsils) from 5 children were included in the study, stained, and analyzed for SHP1, SHP2, PTEN, and HePTP expression (Figure 1, Tables 3-5 ). SHP1 was found exclusively in the cytoplasm with intensities graded between 1 and 3. In 4 out of 5 controls, the expression in terms of percent stained B cells was high, 51-100% (Figure 1 , Table 
. indicates no data due to poor tissue quality or that the samples have not been stained. The samples were stained for the GC markers CD10 and Bcl6, for Bcl2 and CD3, and for the proliferation marker PCNA. For scoring percent positively stained tumor cells, a 25% cutoff was used. 0-25% was considered a negative (-) protein expression and 26-100% a positive (+) protein expression.
3). SHP2 was found in both cytoplasm and nucleus and the cytoplasmic intensity was graded 3 in 4 out of 5 controls (Figure 1 and Table 3 ). Further, all controls showed cytoplasmic SHP2 staining in a high percentage of the B cells, 51-100%, (Table 4 ) and the nuclear staining ranged between 10 and 40% positive cells (Table 5 ). PTEN was expressed in both cytoplasm and nucleus in lymphoid B cells in the control tissue. The staining intensity for cytoplasmic PTEN was graded intermediate to high (grades 2-3) and in all cases a high percentage (51-100%) of cells expressed the protein (Tables 3  and 4 ). Nuclear PTEN staining was found in 20-40% of the control B cells (Table 5) . HePTP was found exclusively in the cytoplasm in all cases and all the controls showed a strong HePTP intensity in a high percentage of cells (Figure 1, Tables 3 and 4) . 
Significantly Lower Staining Intensity of Cytoplasmic PTEN and HePTP but Higher Nuclear SHP2 Expression in BL Cases Compared to Control Lymphoid Tissue
In total, 19 BL, 3 LBCL, and 4 unspecified B-NHL cases were stained and analyzed for the expression of SHP1, SHP2, PTEN, and HePTP (Figure 2 , Tables 3-5). As in the control tissue, SHP1 and HePTP were found in the cytoplasm, whereas SHP2 and PTEN were expressed in both cytoplasm and nucleus. Cytoplasmic staining intensity and percent positively stained cells were determined and presented in Tables 3 and 4 . The staining results obtained for either the BL cases alone or all lymphoma cases, respectively, were compared to normal controls in a Mann-Whitney test. When the BL cases alone were analyzed for statistical calculations and comparisons to control tissue, the statistical results were similar to those obtained for all B-cell lymphoma cases (Tables 3-5 ).
The analysis revealed that the staining intensity for cytoplasmic PTEN and HePTP were significantly lower in B-cell lymphoma tissue compared to controls, but no differences in percent positively stained cells could Note. The pediatric B-cell lymphoma and lymphoid control tissue were stained and analyzed for the cytoplasmic expression of SHP1, SHP2, PTEN, and HePTP. The staining intensity was graded 0 = negative, 1 = weak, 2 moderate, 3 = strong, 4 = very strong. The staining results obtained for either the BL cases alone or all lymphoma cases (all L), respectively, were compared to normal controls in a Mann-Whitney test.
be detected (Tables 3 and 4) . No significant differences between B-cell lymphoma and controls were observed for SHP1 and SHP2 in staining intensity. SHP1 proved to be similarly expressed in malignant and control tissue, in both staining intensity and percent positively stained cells. No significant differences were found between controls and tumor cells for any of the cytoplasmic proteins (Table 4) . Nuclear SHP2 was found to be Note. The pediatric B-cell lymphoma and lymphoid control tissue were stained and analyzed for percentage of stained B-cells for cytoplasmic SHP1, SHP2, PTEN, and HePTP. For scoring percent stained cells, a 25% cutoff was used. 26-50% was considered an intermediate expression and 51-100% a high protein expression. The staining results obtained for either the BL cases alone or all lymphoma cases (all L), respectively, were compared to normal controls in a Mann-Whitney test.
expressed in a higher percentage of B cells in BL and LBCL cases compared to controls, whereas 3 out of 4 cases diagnosed with unspecified B-NHL displayed similar levels of nuclear SHP2 as the controls (Table 5) .
DISCUSSION
Tyrosine phosphorylation is a key mechanism for signal transduction in multicellular organisms and processes that are regulated by this system include activation, proliferation, differentiation, cell motility, and transportation of molecules into or out of cells [8, 11, 12] . In this limited study of pediatric nonlymphoblastic B-cell lymphoma, a correlation with earlier findings [3, 13] was found with numbers of BL patients who presented with .716
Note. The pediatric B-cell lymphoma and lymphoid control tissue were stained and analyzed for the nuclear expression of SHP2 and PTEN. For scoring percent stained cells, a 25% cutoff was used. 26-50% was considered an intermediate expression and 51-100% a high protein expression. The staining results obtained for either the BL cases alone or all lymphoma cases (all L), respectively, were compared to normal controls in a Mann-Whitney test.
limited-stage disease I or II (35% in this study), while 65% had widespread disease, stage III or IV. The immunophenotype suggests a follicle center origin for BL [3] . Indeed, both BL and follicular lymphoma are derived from the GC stage of differentiation [14] . In our study, PCNA staining analysis showed a very high proliferation index of the pediatric tumor cells
FIGURE 2
The expression of SHP1, SHP2, PTEN, and HePTP in one selected pediatric BL and one selected pediatric LBCL case. For the BL case, cytoplasmic staining intensity was graded 3 (SHP1), 3 (SHP2), 1 (PTEN), and 3 (HePTP). For the LBCL case, the staining intensity was graded 3 (SHP1), 1 (SHP2), 3 (PTEN), and 3 (HePTP).
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M. Fridberg et al. in all cases. In adult diffuse large B-cell lymphoma (DLBCL), two subgroups have been identified using cDNA microarrays, which differ in their ability to be cured by the multiagent chemotherapy that is used at present [15] [16] [17] . The GC subgroup expresses genes characteristic of normal GC B cells and has been associated with a better outcome, whereas the activated B-cell-like (ABC) group expresses genes characteristic of activated blood B cells and has been associated with a poor outcome. Bcl6, CD10, and MUM1/IRF4 have been shown to be differently expressed in the GC and non-GC subgroups using gene expression arrays as well as immunohistochemistry [15] [16] [17] [18] . Both CD10 and Bcl6 are considered GC markers, while IRF4 has been found to be expressed in plasma cells and a subset of cells in the apical light zone of the GC [19] [20] [21] [22] . We have analyzed 26 cases of pediatric B-cell lymphomas for the expression of SHP1, SHP2, PTEN, and HePTP and compared the expression to pediatric control lymphoid tissue. While SHP1 has been shown to be involved mainly as an antagonist to the growth-promoting potentials of receptor PTKs, the role of SHP2 is more complex, indicating both positive and negative roles [23, 24] . In this study, we detected no significant differences in SHP1 protein expression when comparing pediatric control lymphoid tissue and B-cell lymphoma tissue. Interestingly, nuclear SHP2 proved to be expressed in a higher percentage of cells in the BL and LBCL cases compared to controls, indicating a possible role for this proto-oncogene in lymphoma.
PTEN, together with p53, is the most frequently mutated tumor suppressor gene in human cancer [25] . In this context, PTEN functions as a lipid phosphatase, downregulating the PI3K-pathway by dephosphorylating its substrate phosphatidylinositol 3,4,5-triphosphate [26] .
In a previous report by Butler et al. [30] , somatic coding/splice site PTEN mutations was reported in 20% of BL cell lines and in 3% of primary NHL cases studied. We have shown that adult GC DLBCL cells display a lower staining intensity of PTEN compared to non-GC DLBCL cells [28] and here we report a significantly lower staining intensity of PTEN in the 17 analyzed pediatric BL samples compared to control lymphoid tissue. HePTP has been identified as an ERK 1/2 PTP and overexpression of HePTP in Jurkat T-cells blocks ERK 1/2 activation after engagement of the T-cell receptor [29] [30] [31] . In T-cells, HePTP also binds and dephosphorylates the mitogen-activated protein (MAP)-kinase family member p38 [32] . These findings indicate tumor suppressor functions for HePTP and in this study we show a lower staining intensity of this PTP in pediatric B-cell lymphomas compared to B cells in control lymphoid tissue. The importance of HePTP is emphasized by the findings that this PTP often is dysregulated in the preleukemic disorder myelodysplastic syndrome as well as in acute myelogenous leukemia [29] .
In summary, here we provide novel information about the expression of SHP1, SHP2, PTEN, and HePTP in childhood B-cell lymphoma tumors and control B cells from children. Two out of 4 analyzed phosphatases, HePTP and PTEN, were downregulated in pediatric B-cell lymphoma tissue compared to lymphoid controls. HePTP is a negative regulator of T-cell antigen receptor signal transduction [32] and PTEN is one of the most frequently mutated tumor suppressor genes in human cancer [25] . Our results might indicate that the two enzymes potentially have a role also in pediatric B-cell lymphoma. BL is a highly aggressive lymphoma, with tumor cells of GC origin that have a high proliferation rate. Due to effective therapeutic chemotherapy, a high survival rate is obtained in children with pediatric BL today. However, precise diagnosis based on histologic, immunophenotypic, and genetic features is still critical. Therefore, knowledge about key enzymes involved in regulating cell signaling is of outmost importance for future improvement of pediatric cancer therapy.
